Novavax COVID-Flu vaccine trial suspended after participant reports nerve damage

The U.S. Food and Drug Administration (FDA) have halted trials for Novavax’s experimental COVID-19-flu combination vaccine and its standalone flu shot after a trial participant reported nerve damage. The participant, who received the COVID-flu vaccine during a Phase 2 trial in January 2023, later developed motor neuropathy — a condition that affects the nerves controlling [...]The post Novavax COVID-Flu vaccine trial suspended after participant reports nerve damage appeared first on National Daily Newspaper.

Read More